Cell Therapy News 17.19 May 16, 2016 | |
| |
TOP STORYExperimental Therapy Halts Treatment-Resistant Brain Tumors Researchers report an experimental therapy that in laboratory tests on human cells and mouse models stops glioblastoma and high-grade gliomas. Testing a multi-step therapeutic strategy, they found a way to use a gene therapy to shut down a gene long-implicated in the formation of high-grade gliomas called Olig2. [Press release from the Cincinnati Children’s Hospital Medical Center discussing online publication in Cancer Cell] Press Release | Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)To explore plasma cell (PC) longevity and humoral immunity in humans, researchers investigated the fate of PCs and their antibodies in adult and pediatric patients who received chimeric antigen receptor-based adoptive T-cell immunotherapy targeting CD19 to treat B-cell lineage malignancies (CTL019). [Blood] Abstract Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing’s Sarcoma Type 1 Ewing’s sarcoma xenograft modeling confirmed dose related safety and tumor response to pbi-shRNA EWS/FLI1 LPX. Toxicology studies in mini-pigs with doses comparable to the demonstrated in vivo efficacy dose resulted in transient fever, occasional limited hypertension at low and high dose assessment and transient liver enzyme elevation at high dose. [Mol Ther] Full Article To circumvent donor-to-donor heterogeneity, which may lead to inconsistent results after treatment of acute graft-versus-host disease with mesenchymal stromal cells generated from single donors, researchers developed a novel approach by generating these cells from pooled bone marrow mononuclear cells of eight healthy third-party donors. [Haematologica] Abstract Researchers used mesenchymal stromal cells as a novel candidate therapeutic tool in a pilot Phase I study for patients affected by progressive supranuclear palsy, a rare, severe and no-option form of Parkinsonism. [J Transl Med] Full Article A bladder acellular matrix (BAM) or BAM loaded with human adipose-derived mesenchymal stem cells was used to repair partial cystectomy of the bladder in a canine model. [Biomed Mater] Abstract Researchers produced an adeno-associated virus 9 (AAV9) coding for a TALEfrat#8– containing 13 repeat variable diresidues able to bind to the proximal promoter of human frataxin gene. [Gene Ther] Full Article Investigators found that 32P-colloid combined with endostatin exhibited higher inhibitory effect upon tumor growth compared with application of 32P-colloid or endostatin alone, although these therapies all significantly inhibited tumor growth compared with saline control group. [Biosci Rep] Abstract Scientists investigated whether attenuation of hyperoxic lung injury with intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells could simultaneously mitigate brain damage in neonatal rats. [Pediatr Res] Abstract | |
| |
REVIEWSTherapeutic Anti-CD3 Monoclonal Antibodies: From Bench to Bedside The authors review preclinical and clinical studies in which intravenous or mucosal administration of anti-CD3 monoclonal antibodies has been employed and provide an outlook on future developments to enhance the efficacy of this promising therapeutic approach. [Immunotherapy] Full Article Visit our reviews page to see a complete list of reviews in the cell therapy research field. | |
| |
SCIENCE NEWSDicerna Reports Potent Preclinical Activity with GalNAc-DsiRNA-EX Conjugates Dicerna Pharmaceuticals, Inc. presented updated preclinical data demonstrating the potency of its proprietary GalNAc-DsiRNA-EX Conjugate technology in enabling direct delivery of RNA interference-based therapy to the liver via subcutaneous injection, with potential utility against multiple therapeutic targets. [Press release from Dicerna Pharmaceuticals, Inc discussing research presented at the 18th Annual TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Conference, Long Beach] Press Release Tocagen to Present Clinical and Preclinical Data Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, announced that results from the clinical investigation of Toca 511 & Toca FC for the treatment of recurrent high grade glioma will be presented. [Press release from Dicerna Pharmaceuticals, Inc. discussing research to be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release | |
| |
INDUSTRY NEWSBiogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs Biogen announced a broad collaboration and alliance with the University of Pennsylvania to advance gene therapy and gene editing technologies. The expansive research and translational development collaboration has multiple objectives, but will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system. [Biogen] Press Release ASillaJen, Inc. and ABL Europe have entered into a commercial manufacturing agreement for SillaJen’s lead product candidate, Pexa-Vec. SillaJen is currently conducting a multinational, randomized, Phase III, open-label study of Pexa-Vec in patients with advanced liver cancer. [SillaJen, Inc. (PR Newswire Association LLC)] Press Release Bayer and BioNTech AG have entered into an agreement to develop novel, first-in-class mRNA vaccines and therapeutics specifically for Animal Health applications. [BioNTech AG] Press Release HemaCare Signs Distribution Agreement with China-Based Partner HemaCare Corporation has expanded its global capabilities through a strategic distribution agreement in China with Shanghai-based MT-Biological Science and Technology Co. Ltd. [HemaCare Corporation (Business Wire)] Press Release Cell Therapy Ltd. announced the granting of the Japan license for its innovative cardiac regeneration medicine, Heartcelâ„¢ (immuno-modulatory progenitor cells) to Daiichi Sankyo. [Cell Therapy Ltd.] Press Release Stem Cell Gene Therapy for Fatal Childhood Disease Ready for Human Trial Scientists who have developed a stem cell gene therapy to reverse a fatal childhood illness have agreed to work with a new therapeutics company to test it in a human trial. [The University of Manchester] Press Release Aduro Biotech, Inc. announced that the Phase IIb ECLIPSE trial did not meet the primary endpoint of an improvement in overall survival for patients with pancreatic cancer who had failed at least two prior therapies in the metastatic setting. [Aduro Biotech, Inc.] Press Release As part of its strategy for market expansion, SiDanSai has officially changed its English name to Innovative Cellular Therapeutics. [Innovative Cellular Therapeutics Co., Ltd. (PR Newswire Association LLC)] Press Release | |
From our sponsor: Free wallchart from Nature Neuroscience – Neural Stem Cells. Request your copy.
| |
POLICY NEWSGlobal Standards for Stem-Cell Research In response to scientific progress and evolving ethical concerns, the International Society for Stem Cell Research (ISSCR) issued updated and extended guidelines for work involving the manipulation of stem cells and the translation of that work into medical therapies. [Nature News] Editorial | Guidelines Contamination Created Controversial ‘Acid-Induced’ Stem Cells Stem cells that were claimed to be created simply by exposing ordinary cells to stress were probably derived from embryonic stem cells, according to the latest investigation into an ongoing scientific scandal. How that contamination occurred, however, remains an open question. [Nature News] Editorial | Summary Report
| |
REGULATORYCBERClinical Investigator Status (Biologics) Notice FDAStandard Preparations, Limits of Potency, and Dating Period Limitations for Biological Products (FR Doc. No:2016-10385) Notice NIHProspective Grant of Exclusive License: Development of Autologous Tumor Infiltrating Lymphocyte Adoptive Cells for the Treatment of Lung, Breast, Bladder, and HPV-Positive Cancers (FR Doc. No:2015-12539) Notice
| |
EVENTSNEW ICCSCE 2016: 18th International Conference on Cell and Stem Cell Engineering Visit our events page to see a complete list of events in the cell therapy community.
| |
JOB OPPORTUNITIESNEW Professor – Hematology and Cell Therapy (Karolinska University Hospital) Scientist – Bioengineering (STEMCELL Technologies Inc.) Scientist – Human Pluripotent Stem Cell Neural Differentiation (STEMCELL Technologies Inc.) Postdoctoral Fellow – 3D Microtissues from Pluripotent Stem Cells (Gladstone Institutes) Postdoctoral Fellow – Gene Therapy for Metabolic Homeostasis (Legacy REsearch Institute) PhD Studentship – Various Projects (Vienna Biocenter) Postdoctoral Fellow – Stem Cell Models of Parkinson’s (University of Oxford) Group Leader – Development and Stem Cells (Monash University) Postdoctoral Fellow – Immunology (The Pirbright Institute) Assistant Professor – Cell Factory Design (Chalmers University of Technology) Postdoctoral Fellow – Non-Viral Gene Delivery (Nanyang Technological University) Postdoctoral Associate – Genetic Medicine (Cornell University) Associate Scientist – Hematopoietic Stem Cell Biology (Editas Medicine) Research Associate – Hematopoietic Stem Cell Biology (Editas Medicine) Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital) Staff Scientist – Cell Therapy Process Development (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cell Therapy News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Cell Therapy News Volume 17.19 | May 16 2016